Literature DB >> 16251321

Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis.

William R Kirkpatrick1, Ana C Vallor, Robert K McAtee, Neil S Ryder, Annette W Fothergill, Michael G Rinaldi, Thomas F Patterson.   

Abstract

Antagonistic effects of combination therapy using amphotericin B (AmB) with agents which block ergosterol synthesis are a concern. Terbinafine was evaluated with AmB to assess antagonism or synergy in a rabbit model of invasive aspergillosis. Terbinafine had relatively little activity but did not demonstrate antagonism against AmB in our model.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16251321      PMCID： PMC1280177          DOI： 10.1128/AAC.49.11.4751-4753.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

2.  Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model.

Authors:  T F Patterson; P Miniter; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

3.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Interactions between triazoles and amphotericin B against Cryptococcus neoformans.

Authors:  F Barchiesi; A M Schimizzi; F Caselli; A Novelli; S Fallani; D Giannini; D Arzeni; S Di Cesare; L F Di Francesco; M Fortuna; A Giacometti; F Carle; T Mazzei; G Scalise
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

5.  Activity of terbinafine against serious fungal pathogens.

Authors:  N S Ryder
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

6.  The diagnosis of invasive aspergillosis by an enzyme-linked immunosorbent assay for circulating antigen.

Authors:  J R Sabetta; P Miniter; V T Andriole
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

7.  Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis.

Authors:  T F Patterson; D George; R Ingersoll; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1991-10       Impact factor: 5.191

8.  Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes.

Authors:  T F Patterson; P Miniter; J Dijkstra; F C Szoka; J L Ryan; V T Andriole
Journal:  J Infect Dis       Date:  1989-04       Impact factor: 5.226

9.  Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis.

Authors:  T F Patterson; A W Fothergill; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

Authors:  Sofia Perea; Gloria Gonzalez; Annette W Fothergill; William R Kirkpatrick; Michael G Rinaldi; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191
  10 in total
  3 in total

1.  In vitro evaluation of the type of interaction obtained by the combination of terbinafine and itraconazole, voriconazole, or amphotericin B against dematiaceous molds.

Authors:  Fernanda Simas Corrêa Biancalana; Luzia Lyra; Angélica Zaninelli Schreiber
Journal:  Antimicrob Agents Chemother       Date:  2011-06-20       Impact factor: 5.191

2.  Use of Antifungal Combination Therapy: Agents, Order, and Timing.

Authors:  Melissa D Johnson; John R Perfect
Journal:  Curr Fungal Infect Rep       Date:  2010-05-01

3.  The effects of caspofungin and voriconazole in an experimental fungal infection of the ear due to Aspergillus.

Authors:  Abdullah Ayçiçek; Zafer Cetinkaya; Halil Kiyici; Fethullah Kenar; Gülşah Aşik; Nuri Kiraz
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-04-02       Impact factor: 2.503
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.